Study S001556

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD

Included trial: extracted data ClinicalTrials.gov record Statistical Analysis Plan (PDF)Study Protocol (PDF)

Registration

Registration: NCT03175120
Acronym: DUAL™ II China
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 453
Start: 2017-05-26
Primary completion: 2019-03-05
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:Insulin degludec/liraglutide; DRUG:Insulin degludec
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1154-6732; REGISTRY:CTR20060909

Registered primary outcomes

Change in HbA1c [Week 0, week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.